These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Past, present, and future therapies for Clostridium difficile-associated disease. Surowiec D; Kuyumjian AG; Wynd MA; Cicogna CE Ann Pharmacother; 2006 Dec; 40(12):2155-63. PubMed ID: 17148650 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Aslam S; Hamill RJ; Musher DM Lancet Infect Dis; 2005 Sep; 5(9):549-57. PubMed ID: 16122678 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Clostridium difficile-associated disease. Leffler DA; Lamont JT Gastroenterology; 2009 May; 136(6):1899-912. PubMed ID: 19457418 [TBL] [Abstract][Full Text] [Related]
12. Clostridium difficile infection in older adults: a review and update on its management. Kee VR Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856 [TBL] [Abstract][Full Text] [Related]
13. Resolution of recurrent Clostridium difficile-associated diarrhea using staggered antibiotic withdrawal and kefir. Bakken JS Minn Med; 2009 Jul; 92(7):38-40. PubMed ID: 19708314 [TBL] [Abstract][Full Text] [Related]
14. Management of Clostridium difficile infection: thinking inside and outside the box. Gerding DN; Johnson S Clin Infect Dis; 2010 Dec; 51(11):1306-13. PubMed ID: 20979491 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Pépin J; Valiquette L; Gagnon S; Routhier S; Brazeau I Am J Gastroenterol; 2007 Dec; 102(12):2781-8. PubMed ID: 17900327 [TBL] [Abstract][Full Text] [Related]
16. Rifaximin in the treatment of recurrent Clostridium difficile infection. Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030 [TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964 [TBL] [Abstract][Full Text] [Related]
18. Update on Clostridium difficile-induced colitis, Part 2. Reinke CM; Messick CR Am J Hosp Pharm; 1994 Aug; 51(15):1892-901; quiz 1958-9. PubMed ID: 7942924 [TBL] [Abstract][Full Text] [Related]
19. [The approach to recurrent infections with Clostridium difficile]. Paz Z; Altman A Harefuah; 2008 Nov; 147(11):864-5, 942. PubMed ID: 19264004 [TBL] [Abstract][Full Text] [Related]
20. The changing face of Clostridium difficile: what treatment options remain? Shen EP; Surawicz CM Am J Gastroenterol; 2007 Dec; 102(12):2789-92. PubMed ID: 18042108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]